Published in F1000Res on August 25, 2017
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol (1986) 35.41
Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin Microbiol Rev (2005) 6.02
Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease--United States, 1998-2003. MMWR Morb Mortal Wkly Rep (2005) 4.39
Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet (2004) 4.10
Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis (2012) 3.46
Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet (2002) 3.30
Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med (2012) 3.12
Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. Mucosal Immunol (2009) 3.01
Vaccination against colonizing bacteria with multiple serotypes. Proc Natl Acad Sci U S A (1997) 2.58
Impact of immunisation on pertussis transmission in England and Wales. Lancet (2000) 2.42
Airborne transmission of Bordetella pertussis. J Infect Dis (2012) 2.34
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A (2013) 2.29
Effect of pneumococcal conjugate vaccine on nasopharyngeal colonization among immunized and unimmunized children in a community-randomized trial. J Infect Dis (2007) 2.29
The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet (1982) 2.05
Adult vaccination coverage--United States, 2010. MMWR Morb Mortal Wkly Rep (2012) 1.95
Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection. Clin Infect Dis (2011) 1.85
Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. JAMA (2016) 1.84
The pneumococcus: carriage, disease and conjugate vaccines. J Med Microbiol (2002) 1.84
First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin. Vaccine (2009) 1.84
Global population structure and evolution of Bordetella pertussis and their relationship with vaccination. MBio (2014) 1.76
The pertussis problem. Clin Infect Dis (2013) 1.76
Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proc Biol Sci (2010) 1.66
The incidence of Bordetella pertussis infections estimated in the population from a combination of serological surveys. J Infect (2005) 1.64
Epidemiological features of pertussis in the United States, 1980-1989. Clin Infect Dis (1992) 1.55
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog (2013) 1.54
Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med (2011) 1.54
Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am J Epidemiol (2005) 1.52
Effect of a nonavalent conjugate vaccine on carriage of antibiotic-resistant Streptococcus pneumoniae in day-care centers. Pediatr Infect Dis J (2003) 1.51
Overview of pertussis: focus on epidemiology, sources of infection, and long term protection after infant vaccination. Pediatr Infect Dis J (2005) 1.47
Epidemiology of vaccine hesitancy in the United States. Hum Vaccin Immunother (2013) 1.45
Caution--mortality ratios ahead. Lancet (2003) 1.44
Uncloaking the meningococcus: dynamics of carriage and disease. Lancet (1999) 1.39
Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics (2009) 1.39
The decline and resurgence of pertussis in the US. Epidemics (2011) 1.38
Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol (2012) 1.37
Pertactin-negative variants of Bordetella pertussis in the United States. N Engl J Med (2013) 1.34
Comparative genomics of prevaccination and modern Bordetella pertussis strains. BMC Genomics (2010) 1.33
Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine (2003) 1.30
Pertactin-negative Bordetella pertussis strains: evidence for a possible selective advantage. Clin Infect Dis (2014) 1.30
The potential indirect effect of conjugate pneumococcal vaccines. Vaccine (2003) 1.28
Pertussis immunisation and control in England and Wales, 1957 to 2012: a historical review. Euro Surveill (2013) 1.27
Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr (1998) 1.27
Adolescent vaccination-coverage levels in the United States: 2006-2009. Pediatrics (2011) 1.24
Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol (2005) 1.23
Multitarget PCR for diagnosis of pertussis and its clinical implications. J Clin Microbiol (2006) 1.21
Pertussis--United States, 2001-2003. MMWR Morb Mortal Wkly Rep (2005) 1.19
Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol (2012) 1.18
Epidemiological impact of vaccination on the dynamics of two childhood diseases in rural Senegal. Microbes Infect (2005) 1.15
Deciphering the impacts of vaccination and immunity on pertussis epidemiology in Thailand. Proc Natl Acad Sci U S A (2013) 1.15
The ins and outs of pertussis toxin. FEBS J (2011) 1.12
Increase of pertussis incidence in 2010 to 2012 after 12 years of low circulation in Spain. Euro Surveill (2014) 1.10
Duration of pertussis immunity after DTaP immunization: a meta-analysis. Pediatrics (2015) 1.07
Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol (2000) 1.07
Pertussis epidemic--California, 2014. MMWR Morb Mortal Wkly Rep (2014) 1.07
Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012. Euro Surveill (2014) 1.04
FHA-mediated cell-substrate and cell-cell adhesions are critical for Bordetella pertussis biofilm formation on abiotic surfaces and in the mouse nose and the trachea. PLoS One (2011) 1.02
Compliance with recommendations and opportunities for vaccination at ages 11 to 12 years: evaluation of the 2009 national immunization survey-teen. Arch Pediatr Adolesc Med (2011) 1.02
Epidemiological evidence for herd immunity induced by acellular pertussis vaccines. Proc Natl Acad Sci U S A (2014) 0.99
Clinical outcome of pertussis in Sweden: association with pulsed-field gel electrophoresis profiles and serotype. APMIS (2007) 0.98
Evaluation of the impact of a pertussis cocooning program on infant pertussis infection. Pediatr Infect Dis J (2015) 0.96
Epidemiology of pertussis in Italy: disease trends over the last century. Euro Surveill (2014) 0.96
Acellular pertussis vaccines in Japan: past, present and future. Expert Rev Vaccines (2005) 0.96
Asymptomatic transmission and the resurgence of Bordetella pertussis. BMC Med (2015) 0.95
Possible options for new pertussis vaccines. J Infect Dis (2014) 0.95
Control of pertussis--lessons learnt from a 10-year surveillance programme in Sweden. Vaccine (2009) 0.92
The impact of adolescent pertussis immunization, 2004-2009: lessons from Australia. Bull World Health Organ (2011) 0.92
Pertussis pathogenesis--what we know and what we don't know. J Infect Dis (2014) 0.92
Analysis of Bordetella pertussis clinical isolates circulating in European countries during the period 1998-2012. Eur J Clin Microbiol Infect Dis (2014) 0.91
The pertussis enigma: reconciling epidemiology, immunology and evolution. Proc Biol Sci (2016) 0.91
Immunization of children with pertussis toxoid decreases spread of pertussis within the family. Pediatr Infect Dis J (1998) 0.90
The virulence factors of Bordetella pertussis: talented modulators of host immune response. Arch Immunol Ther Exp (Warsz) (2013) 0.89
Maternal and neonatal vaccination protects newborn baboons from pertussis infection. J Infect Dis (2014) 0.87
Humoral immunity 5 years after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine. Vaccine (2007) 0.86
Mucosal immune responses to meningococcal conjugate polysaccharide vaccines in infants. Pediatr Infect Dis J (2002) 0.85
Pertussis transmission in England and Wales. Lancet (2000) 0.84
Do we need a new vaccine to control the re-emergence of pertussis? Trends Microbiol (2014) 0.83
The baboon model of pertussis: effective use and lessons for pertussis vaccines. Expert Rev Vaccines (2014) 0.83
Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine. Vaccine (2011) 0.83
Comparison of Three Whole-Cell Pertussis Vaccines in the Baboon Model of Pertussis. Clin Vaccine Immunol (2015) 0.82
Pertussis in developed countries. Lancet (2002) 0.82
Protecting the herd: the remarkable effectiveness of the bacterial meningitis polysaccharide-protein conjugate vaccines in altering transmission dynamics. Trans Am Clin Climatol Assoc (2011) 0.81
NSW annual vaccine-preventable disease report, 2010. N S W Public Health Bull (2011) 0.81
Pertussis vaccination beyond childhood. Lancet (2005) 0.81
Surveillance of infant pertussis in Sweden 1998-2012; severity of disease in relation to the national vaccination programme. Euro Surveill (2015) 0.81
The impact of parental postpartum pertussis vaccination on infection in infants: A population-based study of cocooning in Western Australia. Vaccine (2015) 0.81
Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria. J Clin Pathol (2004) 0.80
Prevalence of asymptomatic Bordetella pertussis and Bordetella parapertussis infections among school children in China as determined by pooled real-time PCR: a cross-sectional study. Scand J Infect Dis (2014) 0.79
Duration of Bordetella pertussis Polymerase Chain Reaction Positivity in Confirmed Pertussis Illness. J Pediatric Infect Dis Soc (2014) 0.79
Pertussis may be the cause of prolonged cough in adolescents and adults in the interepidemic period. Braz J Infect Dis (2014) 0.78
Utilization of multiple real-time PCR assays for the diagnosis of Bordetella spp. in clinical specimens. Methods Mol Biol (2013) 0.77
The relationship between pertussis symptomatology, incidence and serology in adolescents. Vaccine (2008) 0.77
Pertussis has re-emerged. Ir Med J (2012) 0.76
New Data on Vaccine Antigen Deficient Bordetella pertussis Isolates. Vaccines (Basel) (2015) 0.76
Live pertussis vaccines: will they protect against carriage and spread of pertussis? Clin Microbiol Infect (2016) 0.76
Antibody kinetics and long-term sero-prevalence in the Italian clinical trial of acellular pertussis vaccines. Dev Biol Stand (1997) 0.75